221 related articles for article (PubMed ID: 37125593)
1. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Johns DG; Campeau LC; Banka P; Bautmans A; Bueters T; Bianchi E; Branca D; Bulger PG; Crevecoeur I; Ding FX; Garbaccio RM; Guetschow ED; Guo Y; Ha SN; Johnston JM; Josien H; Kauh EA; Koeplinger KA; Kuethe JT; Lai E; Lanning CL; Lee AYH; Li L; Nair AG; O'Neill EA; Stoch SA; Thaisrivongs DA; Tucker TJ; Vachal P; van Dyck K; Vanhoutte FP; Volckaert B; Wolford DG; Xu A; Zhao T; Zhou D; Zhou S; Zhu X; Zokian HJ; Walji AM; Wood HB
Circulation; 2023 Jul; 148(2):144-158. PubMed ID: 37125593
[TBL] [Abstract][Full Text] [Related]
2. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
3. Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
Ballantyne CM; Banka P; Mendez G; Garcia R; Rosenstock J; Rodgers A; Mendizabal G; Mitchel Y; Catapano AL
J Am Coll Cardiol; 2023 Apr; 81(16):1553-1564. PubMed ID: 36889610
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
[TBL] [Abstract][Full Text] [Related]
5. MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment.
Burnett JR; Hooper AJ
Expert Opin Investig Drugs; 2023; 32(10):873-878. PubMed ID: 37815341
[TBL] [Abstract][Full Text] [Related]
6. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
7. Oral PCSK9 Inhibitors.
Agarwala A; Asim R; Ballantyne CM
Curr Atheroscler Rep; 2024 May; 26(5):147-152. PubMed ID: 38536608
[TBL] [Abstract][Full Text] [Related]
8. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
9. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
[TBL] [Abstract][Full Text] [Related]
10. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
11. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
Wang Y; Liu ZP
Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
14. A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo.
Suchowerska AK; Stokman G; Palmer JT; Coghlan PA; Pieterman EJ; Keijzer N; Lambert G; Chemello K; Jaafar AK; Parmar J; Yan L; Tong Y; Mu L; Princen HMG; Bonnar J; Evison BJ
J Lipid Res; 2022 Nov; 63(11):100293. PubMed ID: 36209894
[TBL] [Abstract][Full Text] [Related]
15. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 in cholesterol metabolism: from bench to bedside.
Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J
Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529
[TBL] [Abstract][Full Text] [Related]
17. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
18. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes.
Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A
Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362
[TBL] [Abstract][Full Text] [Related]
19. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
Smith KW; White CM
J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
[TBL] [Abstract][Full Text] [Related]
20. New Oral PCSK9 Inhibitor: "MK-0616".
Siddiqui Z; Frishman W
Cardiol Rev; 2024 Jan; ():. PubMed ID: 38285643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
